Centene Co. (NYSE:CNC) Shares Acquired by Polianta Ltd

Polianta Ltd increased its holdings in Centene Co. (NYSE:CNC) by 41.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,100 shares of the company’s stock after acquiring an additional 6,500 shares during the quarter. Centene makes up about 0.6% of Polianta Ltd’s holdings, making the stock its 21st biggest position. Polianta Ltd’s holdings in Centene were worth $1,338,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of CNC. Harris Associates L P increased its holdings in shares of Centene by 5.7% in the third quarter. Harris Associates L P now owns 26,314,183 shares of the company’s stock valued at $1,980,932,000 after purchasing an additional 1,420,825 shares during the period. State Street Corp increased its stake in Centene by 0.5% in the 3rd quarter. State Street Corp now owns 23,468,159 shares of the company’s stock valued at $1,766,683,000 after buying an additional 111,654 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Centene by 3.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,768,534 shares of the company’s stock worth $434,255,000 after buying an additional 194,566 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Centene by 14.2% in the 2nd quarter. Legal & General Group Plc now owns 5,113,759 shares of the company’s stock worth $339,042,000 after acquiring an additional 636,683 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Centene by 22.9% during the second quarter. AQR Capital Management LLC now owns 4,461,517 shares of the company’s stock worth $295,799,000 after acquiring an additional 832,318 shares during the period. Institutional investors and hedge funds own 93.63% of the company’s stock.

Insider Buying and Selling

In other Centene news, Director H James Dallas bought 1,693 shares of the business’s stock in a transaction on Monday, December 16th. The shares were purchased at an average price of $59.01 per share, with a total value of $99,903.93. Following the completion of the acquisition, the director now directly owns 1,693 shares of the company’s stock, valued at approximately $99,903.93. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew Lynn Asher bought 17,200 shares of Centene stock in a transaction on Wednesday, November 13th. The shares were purchased at an average cost of $58.14 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the chief financial officer now directly owns 486,847 shares in the company, valued at $28,305,284.58. This trade represents a 3.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 45,010 shares of company stock valued at $2,660,276. Company insiders own 0.29% of the company’s stock.

Centene Price Performance

CNC stock opened at $62.19 on Friday. The stock has a 50-day moving average price of $60.12 and a two-hundred day moving average price of $67.33. The company has a market cap of $31.40 billion, a PE ratio of 10.80, a price-to-earnings-growth ratio of 0.83 and a beta of 0.45. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Centene Co. has a 12-month low of $55.03 and a 12-month high of $81.42.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Sanford C. Bernstein dropped their price objective on Centene from $96.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Robert W. Baird cut their price target on shares of Centene from $83.00 to $66.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Oppenheimer decreased their price objective on shares of Centene from $95.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, December 13th. Wells Fargo & Company reduced their price target on shares of Centene from $91.00 to $90.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Truist Financial lowered their price target on Centene from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, Centene presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.92.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.